Letters sent to healthcare professionals in November 2016

A summary of recent letters sent to relevant healthcare professionals, to inform them of updated safety information.

From:
Medicines and Healthcare products Regulatory Agency
Published
14 December 2016
Therapeutic area:
Cancer, Dermatology, Immunosuppression and transplantation, Infectious disease, Psychiatry and Rheumatology

In November 2016, the following letters were sent to relevant healthcare professionals:

  • apremilast (Otezla鈻�): risk of
  • lenalidomide (Revlimid鈻�): new advice about

Article citation: Drug Safety Update vol 10 issue 5, December 2016: 3.

Updates to this page

Published 14 December 2016